SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Mahamaya Lifesciences informs about disclosure

10 Mar 2026 Evaluate
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Mahamaya Lifesciences has informed that the Board of Directors of the Company, through a circular resolution passed on 10th March 2026, has approved the utilisation of the unutilised Initial Public Offer (IPO) proceeds in subsequent fiscal years i.e., up to March 31, 2028, in a phased manner.

The above information is a part of company’s filings submitted to BSE.

Mahamaya Lifescience Share Price

173.05 8.75 (5.33%)
10-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
UPL 644.80
PI Industries 2952.55
Bayer CropScience 4794.65
Sharda Cropchem 1057.70
Sumitomo Chemical 418.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×